Welcome to our dedicated page for Quantum BioPharma news (Ticker: QNTM), a resource for investors and traders seeking the latest updates and insights on Quantum BioPharma stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Quantum BioPharma's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Quantum BioPharma's position in the market.
Quantum BioPharma (NASDAQ: QNTM) has successfully completed its Phase 1 Multiple Ascending Dose clinical trial for Lucid-21-302 (Lucid-MS), a novel multiple sclerosis drug. The Safety Review Committee confirmed the drug was well-tolerated with no safety concerns or serious adverse events reported.
Lucid-MS is a first-in-class, non-immunomodulatory, neuroprotective compound featuring a unique mechanism of action. Preclinical models demonstrated its ability to stabilize the myelin sheath surrounding nerve fibers, potentially protecting against demyelination - a key characteristic of MS that leads to progressive disability.
Following this milestone, the company is preparing to advance to Phase 2 trials in MS patients, moving closer to their goals of drug approval and commercialization.
Quantum BioPharma (NASDAQ: QNTM) has expanded its cryptocurrency holdings with an additional USD $1,000,000 investment in Bitcoin (BTC) and other cryptocurrencies, bringing its total crypto investment to USD $2,000,000. The investment, approved by the Board of Directors, is part of the company's strategic efforts to hedge against the Canadian dollar and potentially provide returns for shareholders.
The company has established infrastructure to accept cryptocurrency for financing and other transactions, with all digital assets being held by a fully compliant custodian. Quantum BioPharma emphasizes its commitment to maintaining compliance with financial and audit regulations while reserving the right to adjust its cryptocurrency holdings based on market conditions.
Quantum BioPharma (NASDAQ: QNTM) has engaged MZ Group to lead its strategic investor relations and financial communications program. MZ will develop and implement a comprehensive capital markets strategy to increase the company's visibility in the investment community.
The company is developing products focused on brain disorders and alcohol health, including unbuzzd™ and rekvry™, which address excessive alcohol use - a problem costing the U.S. approximately $249 billion annually. Additionally, Quantum is working on a potential first-in-class treatment for demyelinating diseases, including Multiple Sclerosis, which affects nearly 1 million people in the U.S. and 2.8 million worldwide.
The MZ engagement involves a two-month initial period at $10,000 per month, with automatic monthly renewals thereafter. The agreement can be terminated by either party with fifteen days' notice.
Quantum BioPharma (NASDAQ: QNTM) has announced the engagement of two agencies to enhance its public relations and investor awareness programs. Enterprise Canada has been retained indefinitely from December 18, 2024, with a structured payment plan including C$10,000 for Phase 1, C$2,500 upon completion, and C$5,000 monthly retainer for Phase 3. They will develop the company's narrative and media relations strategy.
Empire Market Ventures has been engaged for three months from February 7, 2025, for US$25,000, to provide investor awareness services including access to exclusive mailing lists and content creation.
The company highlighted its key products: unbuzzd™, a rapid alcohol detoxification beverage; rekvry™ for alcohol misuse treatment in healthcare settings; and LUCID-21-302, a new chemical entity targeting multiple sclerosis. The CEO announced that unbuzzd™'s RTD formulation is expected in Q1 2025, following successful clinical trials.
Quantum BioPharma (NASDAQ: QNTM) announced that its licensee Celly Nutrition , developer of unbuzzd™ (a beverage that accelerates alcohol metabolism), has engaged a leading New York Investment Bank to raise up to $10 million USD and explore an IPO on a major US exchange.
Quantum BioPharma owns 25.71% of Celly Nutrition and receives 7% royalty on unbuzzd™ sales until reaching $250 million, after which it drops to 3% in perpetuity. The company retains full rights to develop similar products for pharmaceutical and medical uses.
The Letter of Engagement signed on February 4, 2025, covers financial advisory services for a potential Go-Public Transaction and managing the proposed public offering. Celly Nutrition plans to use the capital to accelerate marketing, retail, and direct-to-consumer sales development of unbuzzd™.
Quantum BioPharma (NASDAQ: QNTM) has announced successful results from a double-blind, randomized, placebo-controlled clinical trial for unbuzzd™, their dietary supplement designed to combat alcohol intoxication effects. The study demonstrated that unbuzzd™ accelerated blood alcohol concentration (BAC) reduction by over 40% within 30 minutes compared to placebo.
Key findings showed statistically significant improvements in:
- Alcohol metabolism acceleration
- Enhanced alertness within 30 minutes
- Stabilized heart rate and blood pressure
- Reduced perceived impairment and mental fatigue
- 67% reduction in hangover headache severity
The trial included participants aged 21-43 of both genders, with weights ranging from 119-232 pounds. The product showed no adverse effects and was well-tolerated by all participants. unbuzzd™ is currently licensed to Celly Nutrition Corp. and available for purchase.
Quantum BioPharma (NASDAQ:QNTM) announced upcoming court proceedings against former CEO Dr. Raza Bokhari on January 24, 2025, seeking to declare him a vexatious litigant. The company has previously won multiple legal battles against Bokhari, who was terminated for cause in July 2021, resulting in approximately $3 million in awards in favor of Quantum BioPharma.
An arbitrator dismissed Bokhari's wrongful dismissal claim and awarded the company CDN$2.81 million plus interest. Additional court costs awarded include $175,000 from Justice Conway and $5,000 from the Court of Appeal. The U.S. District Court granted judgment in favor of Quantum BioPharma, including various monetary awards with interest rates ranging from 4% to 6%. Bokhari has appealed this judgment and provided a supersedeas bond for USD $2,882,441.48 pending the United States Court of Appeals decision.
Quantum BioPharma (NASDAQ:QNTM) announces its dual listing on Upstream, a MERJ Exchange market and global securities trading app, starting January 14, 2025, at 10:00am EST. The company, focused on developing treatments for neurodegenerative, metabolic, and alcohol misuse disorders, will maintain its listings on Nasdaq, Canadian Securities Exchange, and Frankfurt exchanges.
The Upstream platform operates 20 hours daily, offering real-time trading and settlement with transparent orderbook features. Non-U.S. investors can access QNTM shares through the Upstream app after completing KYC verification. Trading will begin once an existing shareholder places a sale offer.
CEO Zeeshan Saeed states this dual listing aims to add value and liquidity while expanding their reach to a global investor base. U.S. persons are restricted from depositing, buying, or selling securities on Upstream.
Quantum BioPharma (NASDAQ:QNTM) has received approval for dual listing on Upstream, a MERJ Exchange market and global securities trading app. Trading will commence on January 14, 2025, at 10:00am ET under the ticker 'QNTM'. The dual listing aims to provide access to a global investor base outside the U.S., enabling trading through various payment methods including credit/debit cards, PayPal, USD, or USDC.
The Upstream platform operates 20 hours daily, 7 days a week, featuring real-time trading and settlement with a transparent orderbook designed to prevent market manipulation. Non-U.S. investors can participate by downloading the Upstream app, completing KYC verification, and following specific share transfer procedures.
The company, which focuses on developing treatments for neurodegenerative and metabolic disorders, views this dual listing as a strategic move to enhance shareholder value by increasing liquidity and improving price discovery.
Quantum BioPharma (NASDAQ:QNTM) has announced the closing of a second tranche of its previously announced offering from December 5, 2024. The company has issued 500 Debenture Units for $500,000. The proceeds will be allocated to the ongoing development of the company's business model and general working capital purposes. All securities issued in this second tranche are subject to a four-month and one-day statutory hold period from the issuance date. The securities are not registered under the U.S. Securities Act and cannot be offered or sold in the United States without registration or an applicable exemption.
FAQ
What is the current stock price of Quantum BioPharma (QNTM)?
What is the market cap of Quantum BioPharma (QNTM)?
